Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 8/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | TERT | O14746 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761752 | 1.00 | EP300 (0.39) | EP300PPARGPPARATERTPTPN1 | |
| SCHEMBL9540427 | 0.98 | EP300 (0.42) | EP300PPARGPPARATERTPTPN1 | |
| SCHEMBL9540432 | 0.98 | EP300 (0.42) | EP300PPARGPPARATERTPTPN1 | |
| SCHEMBL29190454 | 0.92 | EP300 (0.39) | EP300PPARGPPARATERTPTPN1 | |
| SCHEMBL29190453 | 0.90 | EP300 (0.42) | EP300PPARGPPARATERTPTPN1 | |
| SCHEMBL29482097 | 0.87 | TSHR (0.45) | EP300PPARGPPARATERTPTPN1 | |
| SCHEMBL29190479 | 0.85 | EP300 (0.32) | EP300F7F3 | |
| SCHEMBL29190464 | 0.85 | EP300 (0.41) | EP300PPARGPPARATERTPTPN1 | |
| SCHEMBL14811100 | 0.83 | CES2 (0.38) | PPARGPPARAPTPN1PPARDHSD17B10 | |
| SCHEMBL14811101 | 0.83 | CES2 (0.38) | PPARGPPARAPTPN1PPARDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0640586-B1 | STILBENE DERIVATIVE AND STILBENE ANALOG DERIVATIVE, AND USE THEREOF | MORINAGA MILK INDUSTRY CO LTD (JP) | 1999-06-09 | — | — | EP | claimed |
| JP-7076583-A | — | — | None | — | — | JP | disclosed |
| US-20220183964-A1 | IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS | FOUNDRY THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-3952847-A1 | IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS | Foundry Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210764-A1 | IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS | FOUNDRY THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10100029-B2 | Combretastatin analogs | BIOVENTURES, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180118710-A1 | COMBRETASTATIN ANALOGS | BIOVENTURES, LLC | 2018-05-03 | — | — | US | disclosed |
| US-9884842-B2 | Combretastatin analogs | BIOVENTURES, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160068506-A1 | COMBRETASTATIN ANALOGS | BIOVENTURES, LLC | 2016-03-10 | — | — | US | disclosed |
| EP-2986596-A2 | COMBRETASTATIN ANALOGS | The Board of Trustees of the University of Arkansas (US) | 2016-02-24 | — | — | EP | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0640586-B1 | STILBENE DERIVATIVE AND STILBENE ANALOG DERIVATIVE, AND USE THEREOF | MORINAGA MILK INDUSTRY CO LTD (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0918746-A1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998006692-A1 | NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| US-5589506-A | ENZYME INHIBITORS FOR LIPOXYGENASE | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| US-5574062-A | COMPOUNDS HAVE 3-ARYL AND 7-HYDROXY OR -ACYLOXY; USE TO INHIBIT 12-LIPOXYGENASE | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1996-11-12 | — | — | US | disclosed |
| JP-H0776583-A | COUMARIN DERIVATIVE AND USE THEREOF | MORINAGA MILK IND CO LTD | 1995-03-20 | — | — | JP | disclosed |
| EP-0640586-A1 | STILBENE DERIVATIVE AND STILBENE ANALOG DERIVATIVE, AND USE THEREOF | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
| JP-H00776583-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118710-A1 | COMBRETASTATIN ANALOGS | HDAC6, HDAC11, HDAC5 | EP300 1522/4885PPARG 2489/4885PPARA 2823/4885 |
| US-10100029-B2 | Combretastatin analogs | HDAC6, HDAC11, HDAC5 | EP300 1522/4885PPARG 2489/4885PPARA 2823/4885 |
| US-20160068506-A1 | COMBRETASTATIN ANALOGS | HDAC6, HDAC11, HDAC5 | EP300 1522/4885PPARG 2489/4885PPARA 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.